Tumor Fraction-Guided Cell-Free DNA Profiling in Meta

Genome Medicine

13, 1-15

DOI: 10.1186/s13073-021-00898-8

Citation Report

#	Article	IF	Citations
1	Geringe Invasivität – hohe Sensitivität. Trillium-Diagnostik, 2021, 19, 94-98.	0.0	0
2	From APC to the Genetics of Hereditary and Familial Colon Cancer Syndromes. Human Molecular Genetics, 2021, 30, R206-R224.	3.5	35
3	Size Distribution of Cell-Free DNA in Oncology. Critical Reviews in Oncology/Hematology, 2021, 166, 103455.	6.9	42
4	The BA-BCS 2021: An Initial "Trial" for Integrating Basic Science and Medical Progress on Breast Cancer in a Latin-American Country. Journal of Mammary Gland Biology and Neoplasia, 2021, 26, 227-234.	3.7	4
5	cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-Free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. Clinical Cancer Research, 2022, 28, 1841-1853.	9.6	10
6	Dynamics of RAS/BRAF Mutations in cfDNA From Metastatic Colorectal Carcinoma Patients Treated With Polychemotherapy and Anti-EGFR Monoclonal Antibodies. Cancers, 2022, 14, 1052.	5.3	9
7	The Utility of cfDNA in TGCT Patient Management: A Systematic Review. Therapeutic Advances in Medical Oncology, 2022, 14, 17588359221090365.	4.2	25
8	Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights From a Pilot Study. Biomedicines, 2022, 10, 1321.	4.9	15
9	Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges. Cancers, 2022, 14, 3275.	5.3	40
10	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. JCO Precision Oncology, 2022, 6, e2200012.	3.8	9
11	The Unique Genomic Landscape and Prognostic Mutational Signature of Chinese Clear Cell Renal Cell Carcinoma. Journal of the National Cancer Center, 2022, 2, 162-170.	22.8	13
12	ESMO Recommendations on the Use of Circulating Tumour DNA Assays for Patients With Cancer: A Report From the ESMO Precision Medicine Working Group. Annals of Oncology, 2022, 33, 750-768.	42.4	780
13	Liquid Biopsy for Children With Central Nervous System Tumours: Clinical Integration and Technical Considerations. Frontiers in Pediatrics, 2022, 10, 957944.	2.4	11
14	Clinical Utility of Plasma Cell-Free DNA in Gliomas. Neuro-Oncology Advances, 2022, 4, ii41-ii44.	4.1	16
15	Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer. Cell Reports, 2022, 41, 111859.	7.7	76
16	An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2023, 24, 1799.	5.9	17
17	Organizing Precision Medicine: A Case Study of Memorial Sloan Kettering Cancer Center's Engagement In/With Genomics. Social Science & Medicine, 2023, 324, 115789.	4.1	12
18	Identification of Somatic Mutations in Plasma Cell-Free DNA From Patients With Metastatic Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2023, 24, 10408.	5.9	13

#	Article	IF	Citations
19	Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era. Journal of Thoracic Oncology, 2023, 18, 1118-1120.	15.0	1
20	Circulating Tumour DNA Testing in Metastatic Breast Cancer: Integration With Tissue Testing. Cytopathology, 2023, 34, 519-529.	1.5	16
21	Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes With Erdafitinib: A Real-World Experience. Clinical Cancer Research, 2023, 29, 4586-4595.	9.6	78
22	Predicting Tumour Content of Liquid Biopsies From Cell-Free DNA. BMC Bioinformatics, 2023, 24, 1-9.	5.8	2
23	Critical Factors in the Analytical Work Flow of Circulating Tumor DNA-Based Molecular Profiling. Clinical Chemistry, 2024, 70, 220-233.	4.1	55
24	Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers. Journal of Molecular Diagnostics, 2024, 26, 413-422.	3.7	21
25	Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients. Genes, 2024, 15, 750.	3.4	10
26	Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-Passage Whole-Genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation. Clinical Orthopaedics and Related Research, 2025, 483, 10.1097/CORR.0000000000003161.	1.9	11
27	Understanding Mechanisms of Resistance to FLT3 Inhibitors in Adult FLT3-Mutated Acute Myeloid Leukemia to Guide Treatment Strategy. Critical Reviews in Oncology/Hematology, 2024, 201, 104424.	6.9	50
28	Novel Liquid Biopsy CNV Biomarkers in Malignant Melanoma. Scientific Reports, 2024, 14, 1-12.	5.2	8
29	Precision Oncology: Current and Future Platforms for Treatment Selection. Trends in Cancer, 2024, 10, 781-791.	20.7	28
30	Binary Classification of Copy Number Alteration Profiles in Liquid Biopsy With Potential Clinical Impact in Advanced NSCLC. Scientific Reports, 2024, 14, 1-12.	5.2	3
31	Combined Analysis of Circulating Tumor DNA and Tumor Tissue to Overcome Osimertinib Resistance (OSIRIS); The Second Line Osimertinib Cohort. Lung Cancer, 2024, 198, 107972.	4.9	5
32	Clinical Utility of Circulating Tumor DNA Profiling in Detecting Targetable Fusions in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2024, 14, 1463341.	3.5	2
33	A Perspective Review on the Systematic Implementation of ctDNA in Phase I Clinical Trial Drug Development. Journal of Experimental and Clinical Cancer Research, 2025, 44, 1-10.	13.9	17
34	A Deep-Learning Model for Quantifying Circulating Tumour DNA From the Density Distribution of DNA-Fragment Lengths. Nature Biomedical Engineering, 2025, 9, 307-319.	29.0	25
35	20 Pathology of Metastatic Spinal and Vertebral Column Neoplasms. , 2025, .		0
36	Circulating Tumor DNA and Response to Cisplatin-Based Chemotherapy in Patients With Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance). European Urology Open Science, 2025, 75, 80-88.	3.5	6

#	Article	IF	Citations
37	Cell-Free DNA: Features and Attributes Shaping the Next Frontier in Liquid Biopsy. Molecular Diagnosis and Therapy, 2025, 29, 277-290.	6.4	29
38	Improving Cell-Free DNA Detection in Advanced-Stage High-Grade Serous Ovarian Cancer Using Combined TP53 Mutational Status and Copy Number Changes. Pathology Research and Practice, 2025, 272, 156038.	3.8	4
39	Phase II Study of Rucaparib and Nivolumab in Patients With Leiomyosarcoma. Journal for ImmunoTherapy of Cancer, 2025, 13, e012020.	11.3	6
40	Baseline Levels and Dynamic Changes of cfDNA, Tumor Fraction and Mutations to Anticipate the Clinical Course of Small Cell Lung Cancer (SCLC) Patients Treated With First-Line Atezolizumab and Chemotherapy: An Hypothesis Generating Study (CATS/ML43257). Journal of Experimental and Clinical Cancer Research, 2025, 44, 1-14.	13.9	4
41	Genomic Landscape of Hormone Therapy-Resistant HR-Positive, HER2-Negative Breast Cancer. Breast Cancer Research and Treatment, 2025, 213, 247-259.	3.9	9
42	Validation of a Liquid Biopsy Assay With Increased Sensitivity for Clinical Comprehensive Genomic Profiling. The Journal of Liquid Biopsy, 2025, 9, 100322.	4.4	1
43	Beyond Tissue in the Era of Liquid Biopsy: Pathologists' Perspectives and Insights. Cytopathology, 2026, 37, 2-14.	1.5	3
44	Low Level of Plasma DNase Is Associated With Worse Clinical Outcome in Testicular Germ Cell Tumor Patients and Exogeneous DNase I Improves (Leverages) Cisplatin Treatment Efficacy. PLoS ONE, 2025, 20, e0336190.	3.2	1
45	Liquid Biopsy in Oncology: Results of a Delphi Consensus Study Endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. The Journal of Liquid Biopsy, 2026, 11, 100453.	4.4	3
46	Neoadjuvant Nivolumab With or Without Ipilimumab for Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2026, 32, OF1-OF11.	9.6	5
47	Liquid Biopsy in Cancer Diagnosis and Prognosis: A Paradigm Shift in Precision Oncology. Frontiers in Molecular Biosciences, 2026, 12, 1708518.	4.5	19
48	A Computational Framework for Sensitive Tumor Detection and Accurate Subtyping Using Shallow Cell-Free DNA Methylome Sequencing. Genome Medicine, 2026, 18, 27.	11.4	1
49	Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection. International Journal of Nanomedicine, 2026, 21, 1-29.	8.7	6
50	Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated With Neratinib Alone or With Trastuzumab in the SUMMIT Basket Trial. Clinical Cancer Research, 2026, 32, 3735-3745.	9.6	5
51	Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma. JCO Precision Oncology, 2026, 10, e2501069.	3.8	2
52	Role of Liquid Biopsy in Genitourinary (GU) Cancers. Expert Review of Molecular Diagnostics, 2026, 26, 461-481.	4.1	0
53	A Prospective National Precision Medicine Trial Evaluating the Feasibility of Blood-Based Molecular Profiling in Patients With Cancer of Unknown Primary (CUP-COMP). British Journal of Cancer, 2026, 135, 1-12.	8.1	0
54	Generalizable Cancer Detection From Ultra-Low-Pass WGS via Deep Contextual Modeling of cfDNA Sequences. Molecular Biomedicine, 2026, 7, 136.	11.8	1

#	Article	IF	Citations
55	Technical Requirements and Platform Considerations for Molecular Residual Disease in Genitourinary Tumors. Urologic Oncology: Seminars and Original Investigations, 2026, .	2.6	0
56	Integrating Molecular Subtypes, Genomics and Functional Dependencies to Identify Context-Specific Therapeutic Vulnerabilities in Small Cell Lung Cancer. Biomarker Research, 2026, 14, 118.	14.2	0